Physician profile
Babak Razi
NPI 1942345970
$3,815.17
in general payments reported to CMS, 2019-2025
22 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $191 · 2021: $638 · 2022: $532 · 2023: $876 · 2024: $820 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.35 |
| Education | $102.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.05 | 2019-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $612.96 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $472.77 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $221.99 | 2020-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $218.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $218.16 | 2023-2025 | |
| Travere Therapeutics, INC. | $184.55 | 2022-2025 | Filspari |
| Ardelyx, INC. | $180.45 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $179.69 | 2022-2024 | Benlysta, Jesduvroq |
| Amgen INC. | $174.20 | 2019-2023 | Parsabiv, Tavneos, Aranesp |
| Calliditas Therapeutics US INC. | $158.56 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $152.58 | 2021-2024 | |
| Akebia Therapeutics INC | $116.75 | 2020-2024 | Auryxia, Vafseo |
| Lilly USA, LLC | $69.58 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Dexcom, INC. | $60.84 | 2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.40 | 2024 | Korlym |
| Biomerieux INC | $24.04 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.15 | 2019-2020 | |
| Cmp Pharma, INC. | $21.28 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.10 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.88 | 2022 | |
| Vanda Pharmaceuticals INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Razi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.